Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508259 | 0.86 | KDR (0.60) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL2860144 | 0.84 | KDR (0.77) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL2853225 | 0.83 | KDR (0.68) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL3511565 | 0.82 | KDR (0.40) | KDRPIK3CDPIK3CG | |
| SCHEMBL13636134 | 0.81 | KDR (0.70) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL4284743 | 0.78 | KDR (0.87) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL4281880 | 0.77 | KDR (0.76) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL4286029 | 0.76 | KDR (1.00) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL13636142 | 0.76 | KDR (0.79) | KDRPDGFRBFLT1AURKAKIT | |
| SCHEMBL4281866 | 0.76 | KDR (1.00) | KDRPDGFRBFLT1AURKAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 983/4885PDGFRB 1509/4885FLT1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.